Published in Parasite on May 01, 2011
Prospective multicenter study of Pneumocystis jirovecii colonization among cystic fibrosis patients in France. J Clin Microbiol (2012) 0.83
Characterizing Pneumocystis in the lungs of bats: understanding Pneumocystis evolution and the spread of Pneumocystis organisms in mammal populations. Appl Environ Microbiol (2012) 0.82
Performances of Four Real-Time PCR Assays for Diagnosis of Pneumocystis jirovecii Pneumonia. J Clin Microbiol (2015) 0.77
Trimethoprim-sulfamethoxazole treatment does not reverse obstructive pulmonary changes in pneumocystis-colonized nonhuman primates with SHIV infection. J Acquir Immune Defic Syndr (2014) 0.76
An Unusual Case of Cystic Fibrosis Associated Pneumocystis jiroveci Pneumonia in an Infant. Case Rep Infect Dis (2016) 0.75
Cystic fibrosis. N Engl J Med (2005) 8.09
Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax (2004) 8.09
Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J (2006) 6.34
Infections as a major preventable cause of human cancer. J Intern Med (2000) 3.96
Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J (2006) 3.89
Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol (2007) 2.50
Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev (1997) 2.36
Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med (2004) 2.05
Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis (2008) 1.89
Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2005) 1.85
Prevalence and clinical predictors of Pneumocystis colonization among HIV-infected men. AIDS (2004) 1.54
Pneumocystis carinii infection in patients with chronic bronchial disease. Lancet (1996) 1.37
Is there a role for microorganisms in the pathogenesis of sarcoidosis? J Intern Med (2003) 1.30
Pneumocystis carinii cell wall beta-glucans initiate macrophage inflammatory responses through NF-kappaB activation. J Biol Chem (2003) 1.21
Pneumocystis: a novel pathogen in chronic obstructive pulmonary disease? COPD (2008) 1.21
Pneumocystis murina infection and cigarette smoke exposure interact to cause increased organism burden, development of airspace enlargement, and pulmonary inflammation in mice. Infect Immun (2008) 1.18
Pneumocystis infection in humans: diagnosis and treatment. Expert Rev Anti Infect Ther (2010) 1.16
Systemic inflammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jiroveci. Clin Infect Dis (2007) 1.13
Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clin Microbiol Infect (2006) 1.09
Viruses and idiopathic pulmonary fibrosis. Eur Respir J (1997) 1.05
Pneumocystis: not just pneumonia. Curr Opin Microbiol (2005) 1.05
Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis (2009) 1.01
Metagenomic analysis of bronchoalveolar lavage samples from patients with idiopathic interstitial pneumonia and its antagonic relation with Pneumocystis jirovecii colonization. J Microbiol Methods (2010) 0.98
Pneumocystis jiroveci isolates with dihydropteroate synthase mutations in patients with chronic bronchitis. Eur J Clin Microbiol Infect Dis (2004) 0.98
Prevalence of colonisation and genotypic characterisation of Pneumocystis jirovecii among cystic fibrosis patients in Spain. Clin Microbiol Infect (2005) 0.97
Advances in the biology, pathogenesis and identification of Pneumocystis pneumonia. Curr Opin Pulm Med (2008) 0.97
Pneumocystis carinii carriage among cystic fibrosis patients, as detected by nested PCR. J Clin Microbiol (2001) 0.96
Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerg Infect Dis (2004) 0.95
Pneumocystis carinii major surface glycoprotein induces interleukin-8 and monocyte chemoattractant protein-1 release from a human alveolar epithelial cell line. Eur J Clin Invest (1999) 0.94
Cystic fibrosis, atopy, asthma and ABPA. Allergol Immunopathol (Madr) (2010) 0.94
Regulation of surfactant phosphatidylcholine secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat. J Clin Invest (1993) 0.94
Apparent absence of Pneumocystis jirovecii in healthy subjects. Clin Infect Dis (2006) 0.94
Climatic factors and Pneumocystis jiroveci infection in southern Spain. Clin Microbiol Infect (2004) 0.93
Prospective cohort study showing changes in the monthly incidence of Pneumocystis carinii pneumonia. Postgrad Med J (2003) 0.89
Seasonal variation of Pneumocystis jirovecii infection: analysis of underlying climatic factors. Clin Microbiol Infect (2009) 0.89
Pneumocystis jirovecii transmission from immunocompetent carriers to infant. Emerg Infect Dis (2008) 0.88
Association between human-Pneumocystis infection and small-cell lung carcinoma. Eur J Clin Invest (2004) 0.85
Pneumocystis carinii pneumonia in patients without predisposing illnesses. Acute episode and follow-up of five cases. Chest (1993) 0.85
Dynamic colonisation by different Pneumocystis jirovecii genotypes in cystic fibrosis patients. Clin Microbiol Infect (2007) 0.83
Pneumocystis jirovecii and cystic fibrosis in France. Scand J Infect Dis (2010) 0.80
[Human reservoirs of Pneumocystis]. Enferm Infecc Microbiol Clin (2009) 0.77
Pneumocystosis pathophysiology. FEMS Immunol Med Microbiol (1998) 0.76
Clinical significance of anti-multiple nuclear dots/Sp100 autoantibodies. Scand J Gastroenterol (2003) 1.43
Pneumocystis carinii infection in patients with chronic bronchial disease. Lancet (1996) 1.37
Pneumocystis jiroveci genotypes in the Spanish population. Clin Infect Dis (2004) 1.27
Immunocompetent hosts as a reservoir of pneumocystis organisms: histological and rt-PCR data demonstrate active replication. Eur J Clin Microbiol Infect Dis (2004) 1.20
Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clin Microbiol Infect (2006) 1.09
Autoantibodies to transcriptional regulation proteins DEK and ALY in a patient with systemic lupus erythematosus. Hum Immunol (1999) 1.02
Autoantibodies to DEK oncoprotein in systemic lupus erythematosus (SLE). Clin Exp Immunol (2000) 1.00
Pneumocystis jiroveci isolates with dihydropteroate synthase mutations in patients with chronic bronchitis. Eur J Clin Microbiol Infect Dis (2004) 0.98
Climatic factors and Pneumocystis jiroveci infection in southern Spain. Clin Microbiol Infect (2004) 0.93
Pneumocystis jirovecii multilocus genotyping profiles in patients from Portugal and Spain. Clin Microbiol Infect (2008) 0.92
Pneumocystis jirovecii pneumonia in developing countries. Parasite (2011) 0.89
Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens. Clin Microbiol Infect (2009) 0.89
Association between human-Pneumocystis infection and small-cell lung carcinoma. Eur J Clin Invest (2004) 0.85
Absence of Pneumocystis carinii carriers among patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis (1998) 0.84
Dynamic colonisation by different Pneumocystis jirovecii genotypes in cystic fibrosis patients. Clin Microbiol Infect (2007) 0.83
Significance of indeterminate reactivity to human T-cell lymphotropic virus in western blot analysis of individuals at risk. Eur J Clin Microbiol Infect Dis (1997) 0.83
Epidemiology of Pneumocystis carinii pneumonia in southern Spain. Clin Microbiol Infect (2004) 0.83
In birds, NHE2 is major brush-border Na+/H+ exchanger in colon and is increased by a low-NaCl diet. Am J Physiol (1998) 0.81
Presence of glomerular basement membrane (GBM) antibodies in HIV- patients with Pneumocystis carinii pneumonia. Clin Exp Immunol (1997) 0.79
Polymorphisms in Pneumocystis jirovecii strains in Spanish children with cystic fibrosis. J Infect Dis (2006) 0.77
Pneumocystis carinii investigation in patients with Wegener's granulomatosis. Br J Rheumatol (1998) 0.77
Evidence for a role of T-helper type 2 cytokines in the acquisition of human immunodeficiency virus syncytium-inducing phenotype. Eur J Clin Invest (1998) 0.76
Does early zidovudine treatment prevent the emergency of syncytium-inducing human immunodeficiency virus? J Infect Dis (1994) 0.75
Predictive value of the presence of P24 antigen in persons with antibodies to human immunodeficiency virus in Spain. Eur J Clin Microbiol Infect Dis (1989) 0.75
Cytokine network and HIV syncytium-inducing phenotype shift. AIDS (1996) 0.75